Latest News

Simbec-Orion Streamlines Trial Execution With Veeva Clinical Applications

08/12/2020

Vault CTMS and Vault eTMF provide complete visibility into trials, enabling CRO to deliver value-added services to sponsors PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS and Veeva Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents. Veeva […]

Read More

Simbec-Orion and Oncodistinct Network agreement to strengthen early phase oncology research

01/10/2020

Providing oncology drug developers with the successful delivery of early phase oncology studies. Slough, Berkshire, United Kingdom: Simbec-Orion announced a charter agreement between the Oncodistinct Network and Simbec-Orion. The agreement strengthens the relationships between Simbec-Orion and the Oncodistinct network of oncology sites, who partner in operations and scientific expertise in the design and conduct of […]

Read More

Exvastat wins a 3.6 million euro grant for COVID-19 trial

19/05/2020

Congratulations to Cambridge Innovation Capital portfolio company Exvastat that has been awarded a grant from the prestigious Innovative Medicines Initiative. The grant will be used to reformulate and study imatinib in the treatment of Covid-19 associated Acute Respiratory Distress Syndrome (ARDS) in collaboration with Vrije Universiteit Amsterdam (VU Amsterdam), KABS Laboratories Inc. and Simbec-Orion. Read […]

Read More

Simbec-Orion Receives The “CRO Of The Year” Award At 2019 European Lifestars AwardsTM

21/01/2020

Celebrating success across life sciences London, UK, November 25th 2019. Simbec-Orion is pleased to announce that it has been recognised as the winner of the CRO of the Year award at the 2019 Lifestars AwardsTM. Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organisations that play such […]

Read More

Oxford Cannabinoid Technology partners with Simbec-Onion on milestone FIH Phase I study

01/01/1970

Simbec-Orion is honoured to have been trusted by Oxford Cannabinoid Technologies to run this milestone first-in-human Phase1 clinical trial of its lead compound, OCT461201 for Postherpetic Neuralgia (PHN) & Irritable Bowel Syndrome. Chief Scientific Officer, Valentino Parravicini recently discussed the significance of partnering with Simbec-Orion for the first-in-human Phase 1 clinical trial of the lead compound, […]

Read More

Got a question?
Get in Touch or Submit an RFI/RFP

Our team is on hand to answer any questions you might have relating to the work we do at Simbec-Orion. Just fill in the form below, making sure to tick the boxes that apply, and we’ll respond as quickly as we can.

Looking to volunteer for a clinical trial?

Visit our dedicated volunteer website here, or email [email protected]

Follow us on Social Media

Name(Required)
Opt In Emails